Lupus Science & Medicine

Controlling cardiovascular risk factors reduces progression of atherosclerosis in a multiethnic cohort of patients with lupus

Objective Patients with SLE have increased risk of both clinical cardiovascular disease (CVD) and subclinical atherosclerosis ...
Lupus Science & Medicine

Serum lipidomic and metabolomic signatures link epicardial adipose tissue to cardiovascular diseases in SLE: a post-hoc analysis

Objective Cardiovascular diseases are a leading cause of morbidity and mortality in SLE. In this target population, ...
Lupus Science & Medicine

Forgotten costs of systemic lupus erythematosus: estimating indirect healthcare costs in a national prospective observational Canadian lupus cohort

Objectives To assess indirect costs (IDC) due to lost productivity in paid/unpaid labour, stratified by sex, in a national ...
lupus.bmj

Prevalence of sarcopenia and its association with clinical features and health-related quality of life in Brazilian women with systemic lupus erythematosus

Objectives To assess the prevalence of sarcopenia and examine its association with clinical features, health-related quality of life (HRQoL), muscle-specific strength and body composition in patients ...
lupus.bmj

Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE

Background Reports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single centre in China led us to perform an explorative phase I trial of ...
lupus.bmj

HNF-1β alleviates podocyte injury in lupus nephritis by maintaining endoplasmic reticulum homeostasis

Objective The current study aims to elucidate the critical function of hepatocyte nuclear factor 1-beta (HNF1-β) in lupus nephritis (LN) by investigating its modulation of the ...
lupus.bmj

Type I interferons in host defence and inflammatory diseases

Type I interferons (IFN) can have dual and opposing roles in immunity, with effects that are beneficial or detrimental to the individual depending on whether IFN pathway activation is transient or ...
lupus.bmj

Accelerated model of lupus autoimmunity and vasculopathy driven by toll-like receptor 7/9 imbalance

Objectives Activation of endosomal toll-like receptor (TLR)7 or TLR9 has been proposed as a critical step for the initiation and development of SLE. Traditional spontaneous lupus models normally ...
lupus.bmj

LBP1 Interim results of an open-label, multicentre, Phase 1/2 study to assess YTB323 (rapcabtagene autoleucel), a CAR T-cell therapy, for severe refractory systemic lupus ...

Objective Patients with severe refractory systemic lupus erythematosus (srSLE) exhibit failure to respond to treatments, progressive organ damage, and high mortality. Traditionally manufactured ...
lupus.bmj

Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial

Objectives To identify predictors of overall lupus and lupus nephritis (LN) responses in patients with LN. Methods Data from the Aspreva Lupus Management Study (ALMS) trial cohort was used to identify ...
lupus.bmj

Living with systemic lupus erythematosus in 2020: a European patient survey

Objective The aim of this study was to analyse the 2020 burden of Systemic Lupus Erythematosus (SLE) in Europe, from the patients’ perspective. Methods In May 2020, Lupus Europe, the European umbrella ...
lupus.bmj

Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE

Objective Quinolinic acid (QA), a kynurenine (KYN)/tryptophan (TRP) pathway metabolite, is an N-methyl-D-aspartate receptor agonist that can produce excitotoxic neuron damage. Type I and II ...